Condensed Consolidated Interim Balance Sheet - USD ($) $ in Thousands	Mar. 31, 2024	Jun. 30, 2023
Current assets
Cash and cash equivalents	$ 6,351	$ 1,535
Prepaid expenses, taxes and other receivables	208	660
Clinical trial deposit	196	1,075
Total current assets	6,755	3,270
Property and equipment, net	691	709
Total assets	7,446	3,979
Current liabilities
Accounts payable and accrued liabilities	1,243	2,784
Total current liabilities	1,341	3,082
Milestone payment liability	183	166
Total liabilities	1,524	3,248
Stockholders' equity
Common stock Authorized 75,000 shares at March 31, 2024 (June 30, 2023 - 75,000), $0.001 par value Issued and outstanding 55,305 issued at March 31, 2024 (June 30, 2023 - 1,692)	55	2
Additional paid-in capital	153,144	141,438
Accumulated deficit	(157,550)	(151,375)
Accumulated other comprehensive income	21	21
Total stockholders' equity	5,922	731
Total liabilities and stockholders' equity	7,446	3,979
Related Party
Current liabilities
Related party payables	98	298
Preferred Stock Series A
Stockholders' equity
Preferred stock	279	279
Preferred Stock Series C
Stockholders' equity
Preferred stock	$ 9,973	$ 10,366